# Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer

Source: https://onco.cc/trials/nct07814859/  
OnCo record `nct07814859` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.

## Summary

Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07814859 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 88 participants, started 2026-08-31 and due to reach its primary completion in 2027-08-31. Interventions recorded: Retlirafusp alfa Injection; Famitinib; AG. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival. Pancreatic eligibility wording from the registry: "Histopathologically-confirmed diagnosis of pancreatic ductal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07814859
- Phase: 2
- Setting: A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT07814859: https://clinicaltrials.gov/study/NCT07814859

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07814859.json